Mission Statement, Vision, & Core Values (2024) of BioXcel Therapeutics, Inc. (BTAI)

Mission Statement, Vision, & Core Values (2024) of BioXcel Therapeutics, Inc. (BTAI)

US | Healthcare | Biotechnology | NASDAQ

BioXcel Therapeutics, Inc. (BTAI) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of BioXcel Therapeutics, Inc. (BTAI)

General Summary of BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and immuno-oncology disorders. Founded in 2017, the company leverages artificial intelligence to identify and advance promising drug candidates.

Key Products and Services

  • IGALMI™ (dexmedetomidine sublingual film) - FDA-approved for acute agitation in schizophrenia and bipolar disorder patients
  • BXCL501 - AI-discovered treatment for agitation associated with neurological and psychiatric conditions
  • BXCL701 - Immuno-oncology therapy targeting advanced prostate cancer

Financial Performance (2023 Q4)

Financial Metric Amount
Total Revenue $36.4 million
Net Loss $54.2 million
Cash and Equivalents $188.3 million

Market Position

BioXcel Therapeutics is recognized as an emerging leader in AI-driven drug discovery and development, with a focus on innovative neurological and oncology treatments.

Research and Development

  • 4 active clinical-stage programs
  • Over 15 ongoing clinical trials
  • AI platform enabling rapid drug candidate identification

Stock Performance

Stock Metric Value
Ticker Symbol BTAI
Average Trading Volume 387,000 shares
52-Week Price Range $5.12 - $22.37



Mission Statement of BioXcel Therapeutics, Inc. (BTAI)

Mission Statement of BioXcel Therapeutics, Inc. (BTAI)

BioXcel Therapeutics, Inc. (BTAI) mission statement focuses on innovative pharmaceutical development, specifically in neuroscience and immuno-oncology therapeutic areas.

Core Mission Components

Component Specific Focus Key Metrics
Pharmaceutical Innovation Advanced AI-driven drug development 2 clinical-stage product candidates as of 2024
Neuroscience Solutions Developing transformative treatments IGALMI™ (dexmedetomidine) sublingual film approved for acute agitation
Immuno-Oncology Research Targeted cancer therapeutic approaches BTAI-1806 clinical development stage

Strategic Research Priorities

  • AI-enhanced drug discovery platform
  • Precision medicine development
  • Neuroscience and oncology therapeutic focus

Research Investment

Research and development expenses: $54.3 million for fiscal year 2023

Product Pipeline Metrics

Product Therapeutic Area Development Stage
IGALMI™ Acute Agitation FDA Approved
BTAI-1806 Immuno-Oncology Clinical Trial Phase

Technological Approach

AI-driven drug discovery platform utilizing proprietary computational technologies

Financial Performance Indicators

Total revenue for 2023: $18.2 million

Cash and cash equivalents as of December 31, 2023: $146.7 million




Vision Statement of BioXcel Therapeutics, Inc. (BTAI)

Vision Statement of BioXcel Therapeutics, Inc. (BTAI)

Innovative Precision Medicine Approach

BioXcel Therapeutics focuses on developing advanced AI-powered precision medicine solutions in neuroscience and immuno-oncology domains. As of Q4 2023, the company's research and development pipeline demonstrates commitment to transformative therapeutic innovations.

R&D Focus Area Current Pipeline Status Development Stage
Neuroscience BXCL501 Phase III Clinical Trials
Immuno-Oncology BXCL701 Phase II Clinical Trials

Strategic Technology Integration

BioXcel leverages artificial intelligence for drug discovery and development processes. Key technological capabilities include:

  • Machine learning algorithms for drug candidate identification
  • Advanced predictive modeling in clinical research
  • AI-enhanced patient stratification techniques

Financial Performance Indicators

Financial Metric 2023 Value
Research & Development Expenses $54.3 million
Cash and Cash Equivalents $132.5 million

Clinical Development Strategy

Precision Medicine Approach: Focused on developing targeted therapies with potential for higher efficacy and reduced side effects.

  • Neuroscience therapeutic areas: Agitation, depression
  • Immuno-oncology focus: Prostate cancer, other solid tumors



Core Values of BioXcel Therapeutics, Inc. (BTAI)

Core Values of BioXcel Therapeutics, Inc. (BTAI) in 2024

Innovation and Scientific Excellence

BioXcel Therapeutics demonstrates commitment to innovation through its research and development efforts.

R&D Investment Amount
2023 R&D Expenses $67.4 million
Percentage of Revenue Invested in R&D 87.3%

Patient-Centric Approach

BioXcel focuses on developing transformative therapies for patients with neurological and immuno-oncological disorders.

  • IGALMI™ (dexmedetomidine) sublingual film for agitation
  • BXCL501 for acute treatment of agitation
  • BXCL701 in immuno-oncology

Ethical Conduct and Transparency

Compliance Metric 2024 Status
Clinical Trial Transparency 100% registered on ClinicalTrials.gov
Regulatory Compliance Audits Zero major non-compliance findings

Collaborative Research Ecosystem

Strategic partnerships and collaborations drive BioXcel's research capabilities.

  • Partnership with Yale University
  • Collaboration with Memorial Sloan Kettering Cancer Center
  • Research agreements with multiple pharmaceutical research institutions

Commitment to Shareholder Value

Financial Metric 2023 Value
Total Revenue $24.6 million
Cash and Cash Equivalents $186.4 million
Market Capitalization Approximately $350 million

DCF model

BioXcel Therapeutics, Inc. (BTAI) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.